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1. INTRODUCTION 
Many biological messages are recognized by the 
binding of the ligands to specific receptors of the 
outer surface of the cell membrane [l-4]. These 
bindings then initiate certain chemical and physi- 
cal changes in the membrane. One of the early 
changes in membrane state is the activation of 
phospholipase A2 (PLA2) [5]. This reaction has 
many important functions such as in biosynthesis 
of prostaglandins, in physicochemical changes of 
biomembranes and in regulation of the activities of 
other membrane bound enzymes. Therefore, the 
activation of membrane bound PLA2 has a key 
role in the mechanisms of cell activation. One of 
the important features of the regulation of PLA2 is 
the dependency of activation on membrane struc- 
ture. Many investigations were carried out on the 
analogies with much better defined systems using 
soluble phospholipase, though this system is essen- 
tially different from those occurring in natural 
membranes. In those studies, it was proposed that 
a particular region of PLA2, so called interface re- 
cognition site, is involved in interaction with phos- 
pholipid structure [6]. Moreover, it was considered 
that phosphatidylcholine can be hydrolysed only 
near the transition temperature where lipid in liq- 
uid crystalline phase and in the gel phase coexist 
]7,81. 
We have therefore applied the phase transition 
release technique to the study of the activation 
mechanism as related to the changes in physiologi- 
cal characteristics of the membrane and bring evi- 
dence that the maximal carboxyfluorescein release 
Phospholipase A2 (Phospholipid liposome) 
Dipalmitoylphosphatidylcholine 
which was observed below 38°C by PLA2 corre- 
sponds to phase transition point of dipalmitoyl 
phosphatidylcholine. 
2. MATERIALS AND METHODS 
2.1. Reagents 
DL-a-Dimyristoyl phosphatidylcholine (DMPC) 
and DL-a-dipalmytoyl phosphatidylcholine 
(DPPC) were purchased from Sigma Chemical Co. 
Phospholipase A2 from porcine pancreas (800 IU/ 
mg) was supplied by Boehringer. All chemicals 
used were of analytical grade and water was de- 
ionized and distilled. 
2.2. Vesicles 
Liposomes were made with DPPC by the meth- 
od described previously [9]. Unilamellar vesicles 
containing carboxyfluorescein (CF) were prepared 
by the method of Klausner et al. [lo]. Lipids (15 
pmol/ml) were dissolved in chloroform-methanol 
(2:l). One ml of DPPC solution was evaporated 
and lyophylized in a test tube. The lipid (15 pmol) 
was hydrated by vortex-mixing for 15 min in 1 ml 
of 0.1 M NaCl-20 mM phosphate buffer (pH 6.8) 
containing 0.1 M carboxyfluorescein (CF) at 50- 
55°C. The vesicles were sonicated at 45-52°C for 
60 min in a 15 ml test tube using a Branson 
sonifier (Type 185). The sample became optically 
clear within 2-5 min and 1.5 ml were applied to a 
Sepharose 4B column (1.5 X 25 cm). The column 
was eluted at 4°C with buffer containing 0.1 M 
NaCl-20 mM phosphate buffer (pH 6.8) and 
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small unilamellar vesicles were fractionated to sup- 
ply the phase transition release experiment. 
2.3. Phase transition release (PTR) 
The PTR curve was obtained by the method of 
Weinstein et al. [ll]. The unilamellar liposome 
suspension was placed in an ice cold small cuvette 
and transferred to the heated (SO’C) small chamber 
of a Shimadzu fluorospectrophotometer (Type 
RF-510). The temperature of the cuvette holder 
was maintained by a water bath and monitored by 
a digital temperature thermister kept above the 
light path in the solution of cuvette. In this case the 
liposome suspension in the original cuvette was 
mixed with a magnetic stirrer. The CF was excited 
at 470 nm and emission was read at 515 nm. To 
determine the fluorescence intensity achieved by 
the release of 100% of the dye from the liposomes, 
5 ~1 of 10% Triton X-100 solution was added to dis- 
solve the vesicles. For the effect of PLA2 on the 
PTR, PLA2 was added to the liposome suspension 
in the medium of 0.1 M NaCl-20 mM phosphate 
buffer (pH 6.8) at 4°C in the presence or absence 
of EGTA (1 mM) or Ca2+ (1 mM). 
2.4. Association of PLA2 with the Iiposomes 
In the presence of 1 mM EGTA, PLA2 was incu- 
bated for 5 min with DPPC liposomes at 4, 22, 38 
and 43°C. The liposomes were separated from 
PLA2 by Ficoll density gradient centrifugation at 
each temperature as described in the previous pa- 
per [9]. The PLA2 associated liposomes were de- 
tected by SDS polyacrylamide gel electrophoresis. 
The relative amount of associated PLA2 was esti- 
mated using a Shimadzu dual beam gel scanner 
(Type CS-900). 
3. RESULTS AND DISCUSSION 
3.1. Increase in PTR of CF by porcine pancreatic 
PLA2 
A change of fluorescence intensity through the 
phase transition point of DPPC liposome was con- 
firmed as shown in tig.1. The PTR curve was 
changed by addition of a small amount of PLA2 
and the change depended on the concentration of 
added enzyme in the presence of 1 mM CaC12 as 
indicated in fig.1. The requirement for maximum 
fluorescence change was about 0.05 pg/ml. But in 
the presence of 1 mM EGTA, a potent inhibitor of 
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Fig.1. The effect of the enzymatic degradation of phos- 
pholipid by PLA2 on the PTR of CF from DPPC lipo- 
somes and its concentration dependency. CF-containing 
unilamellar DPPC liposomes were incubated with vari- 
ous concentrations of pancreatic PLA2 in the medium of 
0.1 M NaCI-20 mM phosphate buffer (pH 6.8) 1 mM 
CaC12 at 0°C and transferred to the cuvette holder at 
50°C. Fluorescence intensity at 5 15 nm was recorded by 
excitation with 470 nm using a Shimadzu spectrofluoro- 
meter. Total fluorescence intensity of CF in the in- 
cubated liposomes was measured after addition of Tri- 
ton X-100. For the half maximal CF release by enzyme 
activity, 50 ng/ml of PLA2 was required. Inserted figure 
shows the per cent change of CF release by the treat- 
ment with PLA2 in the presence of CaCll. 
PLA2 due to its chelating action of Ca2+, the re- 
quired amount of enzyme for maximum change 
was increased remarkably to 0.6 mg/ml (tig.2). 
Namely this result shows that the change in the 
PTR curve in the presence of PLA2 and Ca2+ is 
due to the enzymatic activity of PLA2 and that the 
changes in the PTR curve by PLA2 in the presence 
of EGTA may be the result of the integration of 
the enzyme protein into the lipid layer of lipo- 
somes as was observed in the case of actin or tu- 
bulin [ 10,121. 
The complicated pattern of CF release from 
liposomes incubated with PLA2 at different con- 
stant temperatures i  shown in fig.3. But the high- 
est velocity of CF release was observed below the 
phase transition point, 15-25°C as indicated in 
iig.3. 
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Fig.2. The effect of PLA2 protein on the phase transition 
release curve of CPPC liposomes. Experimental con- 
ditions were as in fig.1 except the increased enzyme con- 
centration and the substitution of EGTA (1 mM) for 
CaC12 in the incubation medium. The requirement for 
enzyme protein for half-maximal CF release was about 
1 mg/ml. Inserted figure shows the per cent change of 
CF release by the treatment with PLA, in the absence of 
CaCl*. - 
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Fig.3. The effect of PLA2 on the release of CF from 
DPPC liposomes at various temperatures. Unilamellar 
DPPC liposomes containing CF were incubated with 
PLA2 (1 ng/ml) in a medium of 0.1 M NaCl-20 mM 
phosphate buffer (pH 6.8) at various temperatures. The 
degree of CF release 30-60 s after incubation was plot- 
ted against temperature. High activity of PLA2 was de- 
tected over the range of 15-30°C. 
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Figd. The effect of PLA2 inhibitor on the phase transi- 
tion release curve of DPPC in the presence of PLA2 and 
CaCl2. Experimental conditions were as in fig. 1. The in- 
hibitor of PLA2 was added to the medium before in- 
cubation. Bromophenacylbromide (BPB), a potent in- 
hibitor of PLA2, inhibited the release of CF from DPPC 
liposomes depending on its concentration. The degree of 
inhibition was expressed in per cent change of CF re- 
lease by the addition of BPB. The concentration for 
half-maximal inhibition was about 30 PM. Inserted lig- 
ure shows the per cent inhibition of PLAz induced CF 
release by the addition of BPB. 
3.2. Effect of PLA2 inhibitors on the PTR curve of 
DPPC liposomes 
Recently two kinds of PLA2 inhibitors were re- 
ported [13]. One class of inhibitors is drugs which 
react with PLA2 directly such as mepacrine, phen- 
termine and bromophenacyl bromide (BPB) and 
the other class are drugs which modify membrane 
fluidity or lower the transition temperature such as 
anesterics, ethrane and trichloroethylene. In the 
experimental system described above, both classes 
of PLA2 inhibitors inhibit release of CF from lipo- 
somes by PLA;, activity below the temperature of 
phase transition (fig.4). The phase transition point 
of DPPC liposomes was shifted to a lower tem- 
perature by the addition of 0.1% (50 PM) tri- 
chloroethylene and the CF release induced by 
PLA2 was completely inhibited by the drug at 0.1% 
(data was not shown). In contrast to this, BPB had 
no effect on the phase transition point as shown in 
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Table 1 
Association of PLA2 with DPPC liposomes at various temperatures 
Temp. (“C) 
Liposome layers (W) Sample zone 
(l.OX.Ol) (l.Ol~l.03) (I.O3L-:.O4) (J.O4L_:.OS) (l.i6) 
4 _** 0*** 0 57.4 42.6 
22 12.5 20.8 22.2 44.4 
38 - 0 0 17.7 82.3 
43 0 - _ 100.0 
* Interface liposome layer (La L 1, L2 or L3) is 1 .OO- 1 .O 1, 1 .O 1- 1.03, 1.03- 1.04 or 1.04- 1.05 specific 
gravity (g/ml) of Ficoll400 respectively. 
** No existence 
* * * Non-associated liposomes 
Pancreatic PLA2 (500 pg/ml) was incubated with DPPC liposomes (15 pmol/ml) at 4,23,38 and 43°C 
for 5 min and protein associated liposomes were separated from incubation mixture by Ficoll density 
gradient centrifugation (100 Ooo X g for 60 min) at each temperature. The numbers express the per 
cent of protein distribution. 
fig.4. The requirement of BPB for the inhibition of 
PTR induced by PLA2 was the same order of con- 
centration as that described by several investiga- 
tors using other biochemical methods. 
3.3. Association of PLA2 with DPPC liposomes 
As described in the previous section, PLA2 ac- 
tivity was observed under conditions where gel and 
liquid crystal states of liposomes lipid coexist. To 
clarify whether PLA2 associates with liposomes 
under same conditions where PLA;? activity is ex- 
hibited, the Ficoll density gradient centrifugation 
technique was applied to separate the enzyme- 
associated liposomes from the incubation mixture 
after the incubation of PLA;! with DPPC liposomes 
in the presence of EGTA (1 mM). As indicated in 
table 1, PLA2 associated with liposomes and sepa- 
rated from the reaction mixture at temperatures 
where enzyme activity can be detected. Even at 
4°C PLA2 was associated but no association was 
observed over 38°C. Namely, it is suggested that 
the PLA2 can associate with liposomes even at 4°C 
without integration but the integration into the 
liposomal lipid layer proceeded in the presence of 
gel and liquid crystal phases as in the case of actin 
or tubulin [ 121. 
From these experimental data we can conclude 
that the PLA2 can interact with substrate in lipo- 
somes under a lower temperature than the phase 
transition point and can integrate into the phos- 
pholipid membrane layer under the condition 
where gel and liquid crystalline phases coexist. 
Furthermore, in this experiment it was determined 
that the PTR method is a useful technique for 
studying the membrane-PLA2 interaction and 
that the activity of very low concentration of PLA2 
can be measured by using the PTR technique. 
REFERENCES 
[I] Flaherty, J.T.O. and Ward, P.A. (1978) Seminars in 
Hematol. 16, 163-174. 
[2] Utsumi, K., Sugihama, K., Miyahara, M., Naito, 
M., Arai, M. and Inoue, M. (1977) Cell Struct. 
Funct. 2, 203-209. 
[3] Utsumi, K., Miyahara, M., Okimasu, E., Sugiyama, 
K. and Inoue, M. (1979) Phys. Chem. Phys. 11, 
365-369. 
[4] Watanabe, S., Morimoto, Y.M., Shiraishi, N., Sano, 
A. and Utsumi, K. (1981) Cell Struct. Funct. 6, 
263-267. 
[5] Hirata, F., Corcoran, B.A., Venkatasubramanias, 
K., Schiffman, E. and Axelrod, J. (1979) Proc. Natl. 
Acad. Sci. USA 76,2640-2643. 
(61 Pieterson, W.A., Vidal, J.C., Volwerk, J.J. and Hass, 
B.H. (1974) Biochemistry 13, 1455- 1469. 
85 
Volume 145, number 1 FEBSLETTERS August 1982 
(71 Op Den Kamp, J.A.F., Degier, J. and Van Deenen, 
L.L.M. (1974) Biochim. Biophys. Acta 345, 253- 
256. 
[S] Op Den Kamp, J.A.F., Kauerz, M. and Van 
Deenen, L.L.M. (1975) Biochim. Biophys. Acta 406, 
169-177. 
[9] Utsumi, K., Okimasu, E., Takehara, Y., Watanabe, 
S., Miyahara, M. and Moromizato, Y. (1981) FEBS 
Lett. 124, 257-260. 
[lo] Klausner, R.D., Kumar, N., Weinstein, J.N., Blu- 
menthal, R. and Flavin, M. (1981) J. Biol. Chem. 
256,5879-5885. 
[I 1] Weinstein, J.N., Klausner, R.D., Innerarity, T., 
Ralston, E. and Blumenthal, R. (1981) Biochim. 
Biophys. Acta 647,270-284. 
[ 121 Utsumi, K., Okimasu, E., Morimoto, Y.M., 
Nishihara, Y. and Miyahara, M. (1982) FEBS Lett.. 
in press. 
1131 Vigo, C., Lewis, G.P. and Piper, P.J. (1980) Bio- 
them. Pharmac. 29,623-627. 
86 
